These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 16752933)

  • 41. Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.
    Abou-Alfa GK; Lewis LD; LoRusso P; Maitland M; Chandra P; Cheeti S; Colburn D; Williams S; Simmons B; Graham RA
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):29-36. PubMed ID: 28523596
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of sunitinib malate in subjects with hepatic impairment.
    Bello CL; Garrett M; Sherman L; Smeraglia J; Ryan B; Toh M
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):699-707. PubMed ID: 20049443
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Part II: Liver function in oncology: towards safer chemotherapy use.
    Field KM; Michael M
    Lancet Oncol; 2008 Dec; 9(12):1181-90. PubMed ID: 19038765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Liver.
    Piñeiro-Carrero VM; Piñeiro EO
    Pediatrics; 2004 Apr; 113(4 Suppl):1097-106. PubMed ID: 15060205
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels.
    Chang Y; Burckart GJ; Lesko LJ; Dowling TC
    J Clin Pharmacol; 2013 Sep; 53(9):962-6. PubMed ID: 23832278
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chaihu-Shu-Gan-San regulates phospholipids and bile acid metabolism against hepatic injury induced by chronic unpredictable stress in rat.
    Jia HM; Yu M; Ma LY; Zhang HW; Zou ZM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Oct; 1064():14-21. PubMed ID: 28886478
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatic drug metabolism in cystic fibrosis: recent developments and future directions.
    Kearns GL
    Ann Pharmacother; 1993 Jan; 27(1):74-9. PubMed ID: 8431626
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolism of the taxanes including nab-paclitaxel.
    Joerger M
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):691-702. PubMed ID: 25394848
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pharmacology of regional chemotherapy of colorectal liver metastases].
    Schalhorn A; Kühl M
    Zentralbl Chir; 1995; 120(10):764-8. PubMed ID: 7502590
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prescribing in patients with abnormal liver function tests.
    Smith E; Desmond P
    Aust Fam Physician; 2013; 42(1-2):30-3. PubMed ID: 23529456
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The use of SAMe in chemotherapy-induced liver injury.
    Vincenzi B; Russo A; Terenzio A; Galvano A; Santini D; Vorini F; Antonelli-Incalzi R; Vespasiani-Gentilucci U; Tonini G
    Crit Rev Oncol Hematol; 2018 Oct; 130():70-77. PubMed ID: 30196914
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Acetaminophen and the liver: damage at therapeutic dose levels?].
    Petersen KU
    MMW Fortschr Med; 2011 Dec; 153 Suppl 4():137-42. PubMed ID: 23964475
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy.
    Conforti A; Magro L; Moretti U; Scotto S; Motola D; Salvo F; Ros B; Leone R
    Drug Saf; 2006; 29(12):1163-72. PubMed ID: 17147462
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report.
    Krens LL; Baas JM; de Jong FA; Guchelaar HJ; Gelderblom H
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):429-33. PubMed ID: 24258455
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Impact of lipid lowering therapy on liver function].
    Paragh G; Fülöp P
    Orv Hetil; 2009 Jun; 150(26):1205-12. PubMed ID: 19546077
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prescribing drugs for patients with liver disease.
    Anand AC; Chawla YK
    Natl Med J India; 1999; 12(5):217-24. PubMed ID: 10613002
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetic variations in cancer patients with liver dysfunction: applications and challenges of pharmacometabolomics.
    Aboel Dahab A; El-Hag D; Moutamed GM; Aboel Dahab S; Abuknesha R; Smith NW
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):465-89. PubMed ID: 27061417
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A problem-oriented approach to liver disease in oncology patients.
    McDonald GB; Frieze D
    Gut; 2008 Jul; 57(7):987-1003. PubMed ID: 18559388
    [No Abstract]   [Full Text] [Related]  

  • 59. [Dangerous drugs in hepatic insufficiency].
    Isal JP; Caulin C
    Med Chir Dig; 1979; 8(5):447-9. PubMed ID: 534025
    [No Abstract]   [Full Text] [Related]  

  • 60. Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib.
    Giri N; Masters JC; Plotka A; Liang Y; Boutros T; Pardo P; O'Connell J; Bello C
    Invest New Drugs; 2015 Aug; 33(4):931-41. PubMed ID: 26048096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.